What drugs are used for PPA?

Current Approaches to Treating Primary Progressive Aphasia (PPA)

Primary Progressive Aphasia (PPA) is a neurological condition that gradually impairs a person’s ability to communicate. Unlike more common forms of dementia that affect memory first, PPA specifically targets language skills—making speaking, reading, and writing increasingly difficult over time.

Currently, there are no FDA-approved medications specifically designed to treat PPA. This is partly because PPA is often linked to underlying neurodegenerative diseases, such as frontotemporal dementia or, in about 30-40% of cases, Alzheimer’s disease (AD). Because of this connection, some physicians take a practical approach and prescribe medications typically used for Alzheimer’s.

Drugs like Exelon (rivastigmine) and Razadyne (galantamine)—both cholinesterase inhibitors—are sometimes used off-label in PPA patients. These medications work by increasing levels of acetylcholine, a neurotransmitter involved in learning and memory, which may help slow language decline in certain individuals. While they don’t stop or reverse PPA, they may offer modest symptomatic support, particularly when Alzheimer’s pathology is suspected.

It's important to note that treatment remains highly individualized. Not every PPA patient responds to these drugs, and effectiveness can vary widely. A comprehensive care plan often includes speech therapy, cognitive support, and caregiver education to manage the challenges of the disease.

Research into targeted treatments for PPA is ongoing, and clinical trials continue to explore new therapeutic options. For now, early diagnosis and a multidisciplinary approach remain key to helping patients maintain communication abilities and quality of life for as long as possible.